Agenda

Tem lugar nos próximos 9 a 11 de Maio o XVI Congresso da Sociedade Ibérica de Citometría, em Salamanca.

Todas as informações sobre o Congresso podem ser encontradas no site do evento www.sic2019.com.

International Conference on Acute Lymphoblastic Leukaemia

Berlin, Germany
May 17-19, 2019
Chairs: Jan Cools (Leuven), Hervé Dombret (Paris), Adele Fielding (London), Mark Litzow (Rochester)

Programme summary:
Major advances have been reached recently in the knowledge of acute lymphoblastic leukaemia (ALL), including the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, identi­ cation of new potentially druggable disease subsets and discovery of predisposing preleukemic events. During the same period of time, progresses have been accomplished in the management of children and adults with ALL, thanks to routine monitoring of measurable residual disease (MRD), administration of intensi­ ed risk-adapted chemotherapy, introduction of targeted therapies and antibodies, followed by the remarkable eff­icacy of antibody-drug conjugates (ADCs), bi speci­fic T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.

This intense research activity has made ALL a fascinating disease, allowing major improvements in patients’ outcome, while providing important proofs of concept for the treatment of cancer in general.

The 1st ESH Translational Conference on ALL is designed to provide time and multiple opportunities for discussions and interactions with internationally recognized physicians and scientists in the ­field.

Consulte aqui o programa provisório

Learning objectives:

• Learn how to optimally diagnose and classify ALL, by combining modern diagnosis algorithms and early MRD monitoring, to rapidly deliver the right treatment to the right patient
• Review the conventional therapeutic options, with a focus on the role of allogeneic haematopoietic stem cell transplantation
• Learn how to optimize the management of individual patients on the basis of individual drug metabolism, tolerance and toxicity
• Acquire improved knowledge of new emerging targeted or immunologic treatments and understand how they might be combined or even eventually replace current conventional treatment options

The programme will include:

• Plenary Sessions
• Introductory and Keynote Lectures
• Roundtables
• Panel Discussions
• Simultaneous Meet the Expert Sessions
• Manned Poster Session

ESH International Conference on Cellular Therapies: Focus on Immune Based Therapeutic Concepts
September 20-22, 2019
Mandelieu Conference Centre, Mandelieu, France
Chairs: Chiara Bonini, Carl June, Max Topp

 The programme will include:

• Plenary Sessions
• Late Breaking Session
• Panel Discussions
• Simultaneous Meet the Expert Sessions
• Manned Poster Session

 Topics:

• Updates in CAR T Cell therapy for B-Cell tumours
• CAR T Cell therapies for acute myeloid leukaemia and multiple myeloma
• Management of resistance and toxicity to CAR T Cells
• Bites and other engineered antibody therapies
• Cellular therapies for Infections
• Non-T Cell therapies (MSC, Gamma-Delta T-Cells, etc.)
• Immune therapy strategies for solid tumours
• Cellular therapies for GVHD (SC, Suicide Genes, etc.)

5th International Conference on Acute Myeloid Leukemia “Molecular And Translational”: Advances In Biology And Treatment
October 24-26, 2019 – Estoril, Portugal
Chairs: Bob Löwenberg, Hartmut Döhner, Martin Tallman

Programme description

The successful biannual ESH Conferences on acute myeloid leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation. Novel technological, molecular and immunologic approaches are rapidly creating novel insights into the biology and therapeutic perspectives of AML. The cutting-edge program of the conference will deal with the molecular and functional features of leukemic stem cells and their interaction with the microenvironment, the role of somatic and germ-line mutations and epigenetic alterations in the biology of AML, the genomics of leukemogenesis, advances in molecular diagnostics and developmental therapeutics with a focus on molecular and immunotherapeutic targeted therapeutics. Special attention will be given to the utility and promise of novel therapeutic agents.

Learning objectives

1. Understand the pathobiology of leukemia and its development with respect to alterations in hematopoietic stem cells, their microenvironment and altered signal transduction pathways.
2. Acquire insight into the possible mechanisms of inherited and preleukemic disorders and genomic instability that predispose to leukemogenesis and predispose also to disease progression.
3. Understand the characterization of a leukemia stem cell and its relationship to disease development and phenotype.
4. Learn about the pathobiologic importance of epigenetic dysregulation in the development of acute myeloid leukemia and its clinical impact.
5. Evaluate the merits and relevance of molecular diagnostics and minimal residual disease assessment in relation to various management decisions.
6. Gain insight into novel therapeutics of acute myeloid leukemia, including knowledge about their mechanisms of action, drug resistance mechanisms, the current developmental status of various targeted drugs and novel antibody-based and cell-transfer based immunotherapeutic approaches and their promises for future clinical application.

Why the meeting will be valuable for participants?

Cell biological, genomic and epigenetic studies have revealed entirely novel insights into the biology of AML, expanded the genomic landscape in unprecedented depth and discovered functional clues of dysregulation. These insights have furnished keys to the development of novel specifically acting therapeutic drugs and provide the opportunity to develop more effective risk adjusted therapeutic approaches. The emphasis of the Conference is on informal interaction among the participants and it intends to enable ample discussion. Scientific presentations by international leaders will provide the current status and a perspective of the exciting developments in the field. In separate sessions results from both basic and clinical research will be explored.

This meeting will be of interest to:

• Ph-students, post docs, junior and senior biologists and practicing clinicians (MD, PhD, MD-PhD), hematologists and oncologists in training
• Residents and biologists still in-training